The European Patent Office (EPO) has published patent application EP4604995A1, detailing combination vaccines designed to protect against coronavirus, influenza, and Respiratory Syncytial Virus (RSV) infections. The patent lists BioNTech SE and Pfizer Inc. as applicants. This publication signifies the granting of intellectual property rights for these specific vaccine formulations.

While this is a patent grant and not a regulatory mandate, it is relevant for pharmaceutical companies and drug manufacturers operating in the vaccine space. Compliance officers should note this development as it pertains to the intellectual property landscape for infectious disease vaccines. No immediate compliance actions are required, but it may influence future research, development, and market strategies for competing or complementary products.